Working… Menu

Regorafenib and Nivolumab in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04030260
Recruitment Status : Recruiting
First Posted : July 23, 2019
Last Update Posted : September 17, 2019
Information provided by (Responsible Party):
Yanhong Deng, Sun Yat-sen University

Brief Summary:

REGONIVO is a Phase Ib study to explore the efficacy and safety of regorafenib in combination with nivolumab in the treatment of gastric cancer and colorectal cancer with MSS. The study enrolled 50 patients with advanced disease, including 25 cases of gastric cancer, 25 cases of colorectal cancer, except for one case of colorectal cancer with MSI-H, and others were MSS type. The results of the study showed that patients with colorectal cancer had an objective response rate (ORR) of 36% and a progression-free survival (PFS) of 6.3 months.

Based on the preliminary results of the REGONIVO study, the aim of this phase 2 study is to explore the safety and efficacy of regorafenib and nivolumab in combination with radiotherapy with or without irinotecan in previously treated metastatic colorectal cancer patients with pMMR/MSS.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic MSS Drug: Regorafenib and Nivolumab in Combination with Radiotherapy Radiation: Radiation therapy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 43 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Regorafenib and Nivolumab in Combination With Radiotherapy With or Without Irinotecan in Patients With pMMR/MSS and Previously Treated Metastatic Colorectal Cancer:a Multicentre, Phase 2 Trial
Actual Study Start Date : July 19, 2019
Estimated Primary Completion Date : July 19, 2020
Estimated Study Completion Date : July 19, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Regorafenib and Nivolumab in Combination with Radiotherapy Drug: Regorafenib and Nivolumab in Combination with Radiotherapy
Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and Nivolumab administered IV at a dose of 3mg/kg every 2 weeks with or without irinotecan administered IV at a fixed dose of 80-100mg every 2 weeks
Other Names:
  • Regorafenib
  • Nivolumab

Radiation: Radiation therapy
Radiation therapy is believed to increase the likelihood of response of immunotherapy

Primary Outcome Measures :
  1. The progression-free survival (PFS) rates at 6 months [ Time Frame: 2 year ]
    The PFS is defined as the time from the start of treatment to the date of first documented PD or death as a result of any cause, whichever occurred first. When a patient was alive and without progression, PFS was censored at the date of the last disease assessment. The PFS rates at 6 months was estimated from Kaplan-Meier curves.

Secondary Outcome Measures :
  1. The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR). [ Time Frame: 2 year ]
  2. Overall Survival (OS) [ Time Frame: 2 year ]
    OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.

  3. Disease Control Rate (DCR) [ Time Frame: 2 year ]
    DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating)

  4. Safety variables will be summarized using descriptive statistics based on adverse events collection [ Time Frame: 2 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
  • Subjects with metastatic colorectal cancer(CRC) (Stage IV).
  • Subjects must have failed at least two lines of prior treatment.
  • Tumor tissues were identified as mismatch repair-proficient (pMMR) by immunohistochemistry (IHC) method or microsatellite stability (MSS) by polymerase chain reaction (PCR).
  • Progression during or within 3 months following the last administration of approved standard therapies which must include a fluoropyrimidine, oxaliplatin and irinotecan.

    • Subjects treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy.
    • Subjects who progress more than 6 months after completion of oxaliplatin containing adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible.
    • Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study.
    • Subjects may have received prior treatment with Avastin (bevacizumab) and/or Erbitux (cetuximab)/Vectibix (panitumumab) (if KRAS WT)
  • Metastatic CRC subjects must have measurable or non measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 1.
  • Life expectancy of at least 3 months.
  • Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol.

Exclusion Criteria:

  • Prior treatment with Regorafenib.
  • Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody, anti-cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T-lymphocyte-associated Protein 4, CTLA-4) antibody or other drug/antibody that acts on T cell costimulation or checkpoint pathways.
  • Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
  • Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization.
  • Cardiological disease including Congestive heart failure, Unstable angina, Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy.
  • Uncontrolled hypertension. (Systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg despite optimal medical management).
  • Pleural effusion or ascites that causes respiratory compromise.
  • Arterial or venous thrombotic or embolic events.
  • Any history of or currently known brain metastases.
  • Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
  • Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 week.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04030260

Layout table for location contacts
Contact: Yanhong Deng, M.D. 86-13925106525

Layout table for location information
China, Guangdong
The Sixth Affiliated Hospital of Sun Yat-sen University Recruiting
Guangzhou, Guangdong, China, 510655
Contact: Yanhong Deng, M.D.    86-13925106525   
Sponsors and Collaborators
Sun Yat-sen University
Layout table for investigator information
Principal Investigator: Yanhong Deng, M.D. Sixth Affiliated Hospital, Sun Yat-sen University

Layout table for additonal information
Responsible Party: Yanhong Deng, Director of Medical Oncology, Clinical Professor, Sun Yat-sen University Identifier: NCT04030260     History of Changes
Other Study ID Numbers: GIHSYSU-16
First Posted: July 23, 2019    Key Record Dates
Last Update Posted: September 17, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Colonic Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases